Ice crystal growth suppression polypeptides and method of making

• US 5,118,792 A
• Filed: 05/10/1989
• Issued: 06/02/1992
• Est. Priority Date: 05/10/1989
• Status: Expired due to Fees

• Current Assignee: Grace Brothers Limited
• Original Assignee: DNA Plant Technology Corporation (SAVIA SA de CV)
• Inventors: McKown, Robert L., Mueller, Gunhild M., Warren, Gareth J.
• Primary Examiner(s): Robinson, Douglas W.
• Assistant Examiner(s): Weber, Jon P.
• Application Number:
  US07/350,481
• Time in Patent Office: 1,119 Days
• Field of Search: 435/68.1, 435/69.1, 435/69.7, 530/350, 514/773, 514/971, 426/321, 426/327, 426/524, 426/656, 426/657
• US Class Current: 530/350
• CPC Class Codes: C07K 14/00 Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
• CPC Class Codes: C07K 14/31 from Staphylococcus (G)
• CPC Class Codes: C07K 14/46 from vertebrates
• CPC Class Codes: C07K 2319/00 Fusion polypeptide
• CPC Class Codes: C07K 2319/02 containing a signal sequence
• CPC Class Codes: C07K 2319/61 containing an enzyme fusion for detection (lacZ, luciferase)
• CPC Class Codes: C07K 2319/705 containing a protein-A fusion
• CPC Class Codes: C12N 15/62 DNA sequences coding for fusion proteins
• CPC Class Codes: C12N 15/81 for yeasts
• CPC Class Codes: C12N 15/8273 for drought, cold, salt resistance

Abstract

Novel methods of improving freezing tolerance of organic materials through the use of antifreeze polypeptides is provided. These polypeptides increase the storage life of foodstuffs and biologics, as well as protect plant products, such as during growth. The antifreeze polypeptides, or their fusion proteins, may be produced chemically or by recombinant DNA techniques, and then purified for a variety of uses.

Claims

1. A fusion protein consisting essentially of a polypeptide exhibiting ice crystal growth suppression activity and a heterologous protein domain selected from the group consisting of Protein A and β

-lactamase, wherein the polypeptide has the formula;

space="preserve" listing-type="equation">X1-X2-X3,

and is selected from the group consisting of;

Saf3 wherein X1 is MAA;

X2 is type 1-type 3-type 3 and X3 is ATAA;

Saf5 wherein X1 is MAA;

X2 is type1-type3 -type3-type3-type3 and X3 is ATAA;

Saf6 wherein X1 is M;

X2 is type1-type3-type3 and X3 is ATAA;

Saf8 wherein X1 is M; and

X2 is type1-type3--type3 and X3 is ATAR; and

Saf10 wherein X1 is M;

X2 is type1-type4-type5 and X3 is ATAR;

and wherein;

type1 is DTASD AAAAAA,

type2 is LTAAN AKAAAE,

type3 is LTAAN AAAAAA,

type4 is LTAAN AAAAAK,

type5 is LTADN AAAAAA,

type6 is ATAAT AAAAAA, and

type7 is ATAAT AAKAAA.

2. A fusion protein according to claim 1, wherein the fusion protein is β

-lactamase-Saf3-β

-lactamase.

3. A fusion protein according to claim 1, wherein the fusion protein is Protein A-Saf5.

4. A fusion protein according to claim 1, wherein the fusion protein is Saf6-Protein A.

5. A fusion protein according to claim 1, wherein the fusion protein is Saf8-Protein A.

6. A fusion protein according to claim 1, wherein the fusion protein is Protein A-Met-Saf10.

7. A fusion protein according to claim 1, wherein the fusion protein is Protein A-Arg-Val-Asp-Ile-Glu-Gly-Arg-Saf10.